JP2016130266A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016130266A5 JP2016130266A5 JP2016083344A JP2016083344A JP2016130266A5 JP 2016130266 A5 JP2016130266 A5 JP 2016130266A5 JP 2016083344 A JP2016083344 A JP 2016083344A JP 2016083344 A JP2016083344 A JP 2016083344A JP 2016130266 A5 JP2016130266 A5 JP 2016130266A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- macular degeneration
- composition according
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 208000002780 Macular Degeneration Diseases 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 10
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- ODLHGICHYURWBS-LKONHMLTSA-N Trappsol Cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 3
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 102100011470 ABCA4 Human genes 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 108010008148 Member 4 Subfamily A ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 206010062766 Stargardt's disease Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000003078 antioxidant Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 230000002335 preservative Effects 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Claims (21)
- 前記化合物が、0.01%w/v〜1.0%w/vで存在する、請求項1〜5のいずれか1項に記載の薬学的組成物。
- 前記化合物が、0.01%w/v〜0.5%w/vで存在する、請求項6に記載の薬学的組成物。
- 前記ヒドロキシプロピル−β−シクロデキストリンが、2−ヒドロキシプロピル−β−シクロデキストリンまたは3−ヒドロキシプロピル−β−シクロデキストリンである、請求項1〜7のいずれか1項に記載の薬学的組成物。
- 前記ヒドロキシプロピル−β−シクロデキストリンが、2−ヒドロキシプロピル−β−シクロデキストリンである、請求項8に記載の薬学的組成物。
- 前記溶液が、5.5〜8.5のpHである、請求項1〜9のいずれか1項に記載の薬学的組成物。
- 前記溶液が、6.5〜7.5のpHである、請求項10に記載の薬学的組成物。
- さらにバッファーを含む、請求項1〜11のいずれか1項に記載の薬学的組成物。
- 前記バッファーが、リン酸バッファーである、請求項12に記載の薬学的組成物。
- さらに保存剤を含む、請求項1〜13のいずれか1項に記載の薬学的組成物。
- 抗酸化剤をさらに含む、請求項1〜14のいずれか1項に記載の薬学的組成物。
- 請求項1〜15のいずれか1項に記載の薬学的組成物を含む、黄斑変性を処置するための薬学的組成物。
- 前記黄斑変性が加齢性黄斑変性(AMD)である、請求項16に記載の黄斑変性を処置するための薬学的組成物。
- 前記AMDが委縮型AMDである、請求項17に記載の黄斑変性を処置するための薬学的組成物。
- 前記AMDが滲出型AMDである、請求項17に記載の黄斑変性を処置するための薬学的組成物。
- 前記黄斑変性が、萎縮型AMDに続発する地図状萎縮である、請求項16に記載の黄斑変性を処置するための薬学的組成物。
- 前記黄斑変性がシュタルガルト病である、請求項16に記載の黄斑変性を処置するための薬学的組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28574509P | 2009-12-11 | 2009-12-11 | |
US61/285,745 | 2009-12-11 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014255880A Division JP6063916B2 (ja) | 2009-12-11 | 2014-12-18 | 黄斑変性の処置のための組成物および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016130266A JP2016130266A (ja) | 2016-07-21 |
JP2016130266A5 true JP2016130266A5 (ja) | 2016-12-01 |
JP6378242B2 JP6378242B2 (ja) | 2018-08-22 |
Family
ID=44145918
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012543284A Active JP5885670B2 (ja) | 2009-12-11 | 2010-12-09 | 黄斑変性の処置のための組成物および方法 |
JP2014255880A Active JP6063916B2 (ja) | 2009-12-11 | 2014-12-18 | 黄斑変性の処置のための組成物および方法 |
JP2016083344A Active JP6378242B2 (ja) | 2009-12-11 | 2016-04-19 | 黄斑変性の処置のための組成物および方法 |
JP2016245212A Pending JP2017052799A (ja) | 2009-12-11 | 2016-12-19 | 黄斑変性の処置のための組成物および方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012543284A Active JP5885670B2 (ja) | 2009-12-11 | 2010-12-09 | 黄斑変性の処置のための組成物および方法 |
JP2014255880A Active JP6063916B2 (ja) | 2009-12-11 | 2014-12-18 | 黄斑変性の処置のための組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016245212A Pending JP2017052799A (ja) | 2009-12-11 | 2016-12-19 | 黄斑変性の処置のための組成物および方法 |
Country Status (4)
Country | Link |
---|---|
US (3) | US9814701B2 (ja) |
JP (4) | JP5885670B2 (ja) |
CA (1) | CA2782015C (ja) |
WO (1) | WO2011072141A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7973025B2 (en) | 2005-05-26 | 2011-07-05 | Neuron Systems, Inc. | Compositions and methods of treating retinal disease |
CA2782015C (en) * | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
SG11201504859YA (en) | 2012-12-20 | 2015-07-30 | Aldeyra Therapeutics Inc | Peri-carbinols |
CN117045653A (zh) | 2013-01-23 | 2023-11-14 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
US10111862B2 (en) * | 2013-01-25 | 2018-10-30 | Aldeyra Therapeutics, Inc. | Traps in the treatment of macular degeneration |
BR112018003250A2 (pt) | 2015-08-21 | 2018-09-25 | Aldeyra Therapeutics Inc | compostos deuterados e usos dos mesmos |
KR20180116416A (ko) | 2016-02-28 | 2018-10-24 | 알데이라 테라퓨틱스, 아이엔씨. | 사이클로덱스트린으로의 알레르기성 안질환의 치료 |
JP7116490B2 (ja) * | 2016-05-09 | 2022-08-10 | アルデイラ セラピューティクス, インコーポレイテッド | 眼の炎症性障害および疾患の組合せ処置 |
MX2019010576A (es) * | 2017-03-16 | 2019-10-07 | Aldeyra Therapeutics Inc | Compuestos polimorficos y usos de los mismos. |
EP3694500A4 (en) | 2017-10-10 | 2021-06-30 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
WO2020033344A1 (en) | 2018-08-06 | 2020-02-13 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
EP3856478A4 (en) | 2018-09-25 | 2022-06-08 | Aldeyra Therapeutics, Inc. | FORMULATIONS FOR THE TREATMENT OF DRY EYE DISEASE |
WO2020180872A1 (en) * | 2019-03-05 | 2020-09-10 | Cornell University | Compositions of matter with activity to remove lipofuscin from retinal cells |
JP2022526917A (ja) | 2019-03-26 | 2022-05-27 | アルデイラ セラピューティクス, インコーポレイテッド | 眼科用製剤およびその使用 |
KR20220058826A (ko) * | 2020-10-29 | 2022-05-10 | 주식회사 피노바이오 | 시신경 보호 대상인 환자에게 점안제로 투여하기 위한 약학 조성물 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2086186A (en) | 1933-10-10 | 1937-07-06 | Us Rubber Co | Treatment of rubber |
US4675332A (en) | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
GB8610981D0 (en) | 1986-05-06 | 1986-06-11 | Ici America Inc | Quinoline amides |
CA2054339C (en) | 1990-11-02 | 2002-12-24 | Francesco G. Salituro | 3-amidoindolyl derivatives |
US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
US5493027A (en) | 1993-01-22 | 1996-02-20 | Board Of Regents, The University Of Texas System | Anticonvulsive agents and uses thereof |
US5597823A (en) | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
CA2261916A1 (en) | 1996-08-01 | 1998-02-12 | Dowelanco Llc | 4-substituted quinoline derivatives having fungicidal activity |
ATE336485T1 (de) | 1997-05-02 | 2006-09-15 | Schering Ag | Substituierte heterocyclen und deren verwendung in arzneimitteln |
WO1999046237A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
AU1735001A (en) * | 1999-12-10 | 2001-06-18 | Senju Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical composition |
FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
CA2416228C (en) * | 2002-01-15 | 2010-07-13 | Olsonet Communications Corporation | Communication nodes for use with a wireless ad-hoc communication network |
US20060014786A1 (en) | 2002-05-17 | 2006-01-19 | Rajeev Raut | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
EP1610772A4 (en) | 2003-03-14 | 2008-06-18 | Univ Washington | RETINOID REPLACEMENT AND OPSIN AGONISTS AND METHOD OF USE THEREOF |
CA2527175A1 (en) | 2003-04-18 | 2004-10-28 | Advanced Medicine Research Institute | Remedies for diseases to be applied to eye |
US20060111318A1 (en) | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
EP2468729B1 (en) | 2003-10-15 | 2013-12-25 | Ube Industries, Ltd. | Novel indazole derivative |
AU2004293105B2 (en) | 2003-11-20 | 2010-09-09 | Othera Holding, Inc. | Amelioration of macular degeneration and other ophthalmic diseases |
US20050197292A1 (en) | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
EP1722766A2 (en) | 2004-02-17 | 2006-11-22 | President And Fellows Of Harvard College | Management of ophthalmologic disorders, including macular degeneration |
US20050234018A1 (en) | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
WO2006002473A1 (en) | 2004-07-02 | 2006-01-12 | Adelaide Research & Innovation Pty Ltd | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes |
CA2585210A1 (en) | 2004-10-28 | 2006-05-11 | Merck & Co., Inc. | Pyrimidine and quinoline potentiators of metabotropic glutamate receptors |
TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
US7973025B2 (en) | 2005-05-26 | 2011-07-05 | Neuron Systems, Inc. | Compositions and methods of treating retinal disease |
NZ590271A (en) | 2006-04-14 | 2011-12-22 | Prana Biotechnology Ltd | 9-hydroxy-3-substituted-4H-pyrido[1,2-a]pyrimidin-4-ones and 9-hydroxy-3-substituted-4H-pyrido[1,2-a]pyrimidin-4-thiones |
CN101611009A (zh) | 2006-07-25 | 2009-12-23 | 伊维沃制药股份有限公司 | 喹啉衍生物 |
MY160052A (en) | 2007-10-05 | 2017-02-15 | Acucela Inc | Alkoxy compounds for disease treatment |
KR20110044291A (ko) | 2008-08-12 | 2011-04-28 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 벤족사졸, 벤즈티아졸 및 관련 유사체 |
WO2010133672A1 (en) | 2009-05-20 | 2010-11-25 | Clanotech Ab | Derivatives of quinoline-3-carboxylic acid and their medical use |
EP2477594A4 (en) | 2009-07-15 | 2013-03-13 | Univ Vanderbilt | ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY |
EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
BR112013017943A2 (pt) | 2011-01-12 | 2018-12-18 | Array Biopharma Inc | benzoazepinas substituídas como moduladores receptores do tipo toll |
WO2012105887A1 (en) | 2011-01-31 | 2012-08-09 | Tim Bowden | Active principle for mitigating undesired medical conditions |
CN117045653A (zh) | 2013-01-23 | 2023-11-14 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
US10111862B2 (en) | 2013-01-25 | 2018-10-30 | Aldeyra Therapeutics, Inc. | Traps in the treatment of macular degeneration |
US10272106B2 (en) | 2014-06-04 | 2019-04-30 | Case Western Reserve University | Compositions and methods of treating diabetic retinopathy |
WO2016085939A2 (en) | 2014-11-24 | 2016-06-02 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
-
2010
- 2010-12-09 CA CA2782015A patent/CA2782015C/en active Active
- 2010-12-09 JP JP2012543284A patent/JP5885670B2/ja active Active
- 2010-12-09 WO PCT/US2010/059719 patent/WO2011072141A1/en active Application Filing
- 2010-12-09 US US13/514,769 patent/US9814701B2/en active Active
-
2014
- 2014-12-18 JP JP2014255880A patent/JP6063916B2/ja active Active
-
2016
- 2016-04-19 JP JP2016083344A patent/JP6378242B2/ja active Active
- 2016-12-19 JP JP2016245212A patent/JP2017052799A/ja active Pending
-
2017
- 2017-10-12 US US15/782,470 patent/US20180092882A1/en not_active Abandoned
-
2023
- 2023-09-01 US US18/241,598 patent/US20240148700A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016130266A5 (ja) | ||
JP2015057437A5 (ja) | ||
JP2017222697A5 (ja) | ||
MX2023003067A (es) | Oxadiazoles fungicidas. | |
JP2016506958A5 (ja) | ||
JP2014521688A5 (ja) | ||
JP2017523143A5 (ja) | ||
JP2016515561A5 (ja) | ||
JP2016505614A5 (ja) | ||
JP2017537066A5 (ja) | ||
JP2016516699A5 (ja) | ||
JP2016507575A5 (ja) | ||
JP2016531126A5 (ja) | ||
JP2018531218A5 (ja) | ||
MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
JP2017521436A5 (ja) | ||
EA201992771A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
JP2015199738A5 (ja) | ||
JP2018521056A5 (ja) | ||
JP2021502388A5 (ja) | ||
JP2016503403A5 (ja) | ||
PH12019500822A1 (en) | Crystalline forms of eravacycline | |
MX2016001095A (es) | Sales de dasatinib en forma cristalina. | |
RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
WO2019099564A8 (en) | Novel imidazopyrimidine compounds and uses thereof |